The WTO Tobacco Rulings: How Trade Law Became the Tobacco Industry's Last Weapon

In 2012, Australia became the first country in the world to require plain packaging of cigarettes—no logos, no brand colors, no distinguishing design elements, just the brand name in a standardized font on a drab olive-brown background with graphic health warnings. The tobacco industry's response was to sue Australia—not in Australian courts, but under international investment law, using a bilateral investment treaty between Australia and Hong Kong (where Philip Morris Asia, the claimant, was based). The industry also supported efforts by several tobacco-producing countries—Ukraine, Honduras, the Dominican Republic, Cuba, and Indonesia—to challenge Australia's plain packaging law at the World Trade Organization. The WTO challenge took nearly a decade to resolve. Australia won, ultimately—the WTO panel upheld the plain packaging law in 2018, and the decision was affirmed on appeal in 2020. But the victory came at an enormous cost: years of legal uncertainty, tens of millions of dollars in litigation expenses, and a chilling effect that deterred other countries from implementing similar measures while the case was pending. The WTO tobacco disputes are a case study in how international trade law can be weaponized to delay, dilute, and deter public health regulation.

The legal framework underlying the WTO challenges is dense and technical, but the core issue is straightforward. The WTO's Agreement on Technical Barriers to Trade (TBT) requires that technical regulations not be 'more trade-restrictive than necessary to fulfill a legitimate objective.' Australia's plain packaging law is a technical regulation (it regulates the characteristics of a product), and it restricts trade (by limiting the use of trademarks, which have commercial value and are protected under international trade law). The question for the WTO panel was whether the plain packaging law was 'more trade-restrictive than necessary' to achieve its public health objective—reducing smoking by reducing the appeal of cigarette packaging. Australia argued that plain packaging, as part of a comprehensive tobacco control strategy, was necessary and evidence-based. The tobacco-producing countries argued that less trade-restrictive alternatives—larger health warnings, public education campaigns—could achieve the same objective. The panel agreed with Australia: the evidence supported the effectiveness of plain packaging, and the alternatives proposed by the complainants would not achieve the same level of public health protection. The decision established an important precedent: public health measures that are evidence-based and non-discriminatory can withstand WTO scrutiny, even when they significantly restrict commercial interests.

But the WTO precedent is narrower than it appears—and the broader landscape of international trade and investment law remains hostile to public health regulation. Investment treaties—bilateral agreements that allow foreign investors to sue host governments for measures that reduce the value of their investments—are a more potent threat than WTO disputes. The Philip Morris v. Australia case was dismissed on jurisdictional grounds (the tribunal found that Philip Morris had restructured its investment to gain access to the treaty after the plain packaging law was announced, constituting an 'abuse of rights'). But the case demonstrated the strategic use of investment arbitration: even when the claim is ultimately dismissed, the years of legal proceedings, the threat of billions in damages, and the uncertainty of the outcome are themselves a deterrent to regulation. The Trans-Pacific Partnership (TPP) and its successor agreements included provisions that would have expanded the scope of investor-state dispute settlement (ISDS) in ways that the tobacco industry would have exploited—provisions that were ultimately limited by the public health community's successful advocacy for a 'tobacco carve-out.' The carve-out is fragile and incomplete: it applies to some agreements but not others, and its scope is contested.

The less visible dimension of trade law's impact on tobacco control is the ongoing harmonization of product standards. The WTO's TBT Agreement encourages members to base their technical regulations on international standards, where they exist. For tobacco products, the relevant international standards are developed by the International Organization for Standardization (ISO)—a body whose tobacco-related standards (for measuring tar, nicotine, and carbon monoxide yields, for example) have historically been influenced by the tobacco industry. The ISO standard for measuring cigarette emissions—the 'ISO smoking regime,' which uses a machine that takes 35-mL puffs over 2 seconds, once per minute—systematically underestimates the actual exposure of human smokers, who smoke more intensively and compensate for low-yield cigarettes by smoking more or inhaling more deeply. The ISO standard has been criticized by the WHO and independent researchers for decades, but it remains the international reference standard under the TBT framework, and countries that adopt more stringent measurement methods face the burden of justifying their deviation from the international standard. The harmonization of standards—ostensibly a technical exercise in trade facilitation—can function as a ceiling on regulatory ambition, locking in the standards that the industry has learned to live with and preventing the development of standards that would actually protect health.

The response of the public health community to the trade-law challenge has been to carve out exceptions for tobacco—to insist that tobacco control measures, because of their unique public health importance, should be exempt from the trade and investment disciplines that apply to other products. The 'tobacco carve-out' in recent trade agreements, the FCTC's assertion that public health should take precedence over trade, and the WHO's increasing engagement with trade-law issues all reflect this strategy. The strategy has been partially successful—the carve-outs exist—but it has limitations. The carve-outs are not universal; they apply to some agreements and some measures but not others. They depend on the continued political will of the governments that negotiate trade agreements—will that can shift with changes in administration. And they rest on the premise that tobacco is uniquely dangerous and uniquely deserving of exemption from trade disciplines—a premise that is true but that may not be sustainable as the nicotine market diversifies into products (vapes, pouches, heated tobacco) whose risk profile is different from cigarettes. The 'tobacco exceptionalism' strategy is a pragmatic response to an immediate threat. It is not a long-term solution to the structural tension between trade law and public health regulation.

The deeper lesson of the WTO tobacco disputes is that trade law is not neutral with respect to public health. The defaults embedded in trade agreements—that regulations should not restrict trade more than necessary, that international standards should be followed, that foreign investors should be compensated for regulatory takings—are defaults that favor commercial interests over public health. Overcoming those defaults requires resources, expertise, and political commitment that are asymmetrically distributed between the parties: the tobacco industry has deep pockets and experienced trade lawyers; the public health community has evidence and moral authority but far fewer resources for litigation. The Australian plain packaging case was a victory, but it was a victory that took ten years, cost millions, and required a level of legal capacity that few developing countries possess. The next country that wants to implement a bold tobacco control measure—a generational ban, a nicotine reduction standard, a comprehensive flavor prohibition—will face the same challenge: the threat of trade litigation, the cost of defending it, and the risk that a less-favorable panel or tribunal will reach a different conclusion. Trade law is the structural environment within which tobacco control operates. Changing that environment—not just carving out exceptions from it—is the unfinished business of the tobacco control movement.

Shareable insight: Australia's plain packaging law was upheld by the WTO—but only after a decade of litigation and millions in legal costs. The tobacco industry didn't need to win the case to achieve its goal: the threat of trade litigation delayed plain packaging laws in dozens of countries, and the cost of defending those laws deters the countries that can least afford it. Trade law is the tobacco industry's weapon of choice—not because it always wins, but because the fight itself is the deterrent.